Fredun Pharmaceuticals Ltd

Fredun Pharmaceuticals Limited announced the allotment of 2,71,200 equity shares with a face value of Rs 10 each to warrant holders, following the conversion of 90,400 warrants. The allotment, approved by shareholders on October 22, 2025, involved investors including Alchemy Capital Management Pvt Ltd, Alchemy Long Term Ventures Fund, Ajay Kumar Aggarwal, Divya Aggarwal, Swati Goel, Sweta Chokhany, Vartika Chokhany, Vivek Dhir, Ceramet Consultants Private Limited, and Nav Ratan Bhaiya. The conversion was adjusted following a 1:2 bonus issue made by the company, with each outstanding warrant now entitling the holder to three equity shares.

Fredun Pharmaceuticals Limited announced the allotment of 2,71,200 equity shares with a face value of Rs 10 each to warrant holders, following the conversion of 90,400 warrants. The allotment, approved by shareholders on October 22, 2025, involved investors including Alchemy Capital Management Pvt Ltd, Alchemy Long Term Ventures Fund, Ajay Kumar Aggarwal, Divya Aggarwal, Swati Goel, Sweta Chokhany, Vartika Chokhany, Vivek Dhir, Ceramet Consultants Private Limited, and Nav Ratan Bhaiya. The conversion was adjusted following a 1:2 bonus issue made by the company, with each outstanding warrant now entitling the holder to three equity shares.

Fredun Pharmaceuticals Ltd share price ticked higher by 3.33% to Rs 1547.75 after the company's net profit surged by 21.80% to Rs 13.13 crore, while revenue from operations slightly gained 8.25% to Rs 227.76 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 25.4 lakh crore, rising 4.13%. It has improved by 0.06% over last one week and advanced by 9.58% in last one month while the market capitalization of Fredun Pharmaceuticals Ltd has sharply increased by 27.07% and 96.33% in the same period respectively. Profit before tax (PBT) of Fredun Pharmaceuticals Ltd stood at Rs 20.55 crore in Q2 FY26, expanding by 127.32% year-on-year, and jumping 82.67% quarter-on-quarter. EBITDA came in at Rs 33 crore, rallying 92.70% YoY and improving 13.37% sequentially. Total expenses posted a minor rise of 6.28% to Rs 199.08 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 179.73 crore, posting a minor increase of 2.47% YoY, while employee benefits expense was at Rs 7.12 crore, collapsing by 19.64% YoY. For the TTM ended FY26, revenue from operations soared by 40.21% to Rs 633.33 crore, while net profit saw a strong growth of 65.25% to Rs 32.62 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 5712% to Rs 94.54 crore, and PBT soared 70.97% to Rs 47.0 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 115.25 crore in FY26, as against Rs 29.06 crore in FY25. Fredun Pharmaceuticals Ltd rallied 343.42% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 3.21% during the same period.

Fredun Pharmaceuticals Limited reported no deviation or variation in the utilization of Rs 111.53 crore raised through a preferential issue during the quarter ended June 30, 2026, according to a regulatory filing. The company, in a statement filed with the BSE Limited, acknowledged observations from the Monitoring Agency, Care Ratings Limited, regarding the classification of certain expenditures and reconciliation of unutilized proceeds, but maintained that these did not constitute a deviation from the originally stated objects for which the funds were raised.

Prathamesh Shantinagar Co-Operative Housing Society Ltd. has initiated legal proceedings seeking ownership of a large housing complex in Mira Road, Thane, encompassing land parcels totaling 12,072 square meters. A hearing is scheduled for August 13, 2026, at the Deputy Registrar, Co-operative Societies in Thane. Separately, a notice has been published regarding a Leave and License agreement for a unit in Swastik Industrial Estate, Kalina, Mumbai, following the death of property owner Hemant Vaman Sawant, to formally establish the lawful possession of Mr. Mahesh Velji Dhadhi. Individuals with claims to either property are urged to present their case, with a 15-day deadline for claims related to the Swastik Industrial Estate property.

Fredun Pharmaceuticals Limited (BSE: FREDUN | 539730) announced its unaudited financial results for the first quarter of fiscal year 2027, reporting total income of Rs 228.25 crore, a 90.44% year-over-year increase, while EBITDA surged by 92.90% to Rs 32.78 crore and net profit rose 94.63% to Rs 13.17 crore. The company, which offers a portfolio spanning generics, cosmeceuticals, nutraceuticals, mobility solutions, and animal healthcare products, also recently allotted 1.10 crore bonus equity shares in a 2:1 ratio to eligible shareholders, increasing its issued and paid-up equity share capital from 55.13 lakh shares to 1.65 crore shares.

Fredun Pharmaceuticals Ltd share price surged by 18.34% to Rs 1313.3 after the company's net profit soared by 21.80% to Rs 13.13 crore, while revenue from operations slightly gained 8.25% to Rs 227.76 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 24.84 lakh crore, easing 5.15%. It has marginally improved by 1.03% over last one week and advanced by 11.63% in last one month while the market capitalization of Fredun Pharmaceuticals Ltd has sharply increased by 40.44% and 65.89% in the same period respectively. Profit before tax (PBT) of Fredun Pharmaceuticals Ltd stood at Rs 20.55 crore in Q2 FY26, rallying 127.32% year-on-year, and surging by 82.67% quarter-on-quarter. EBITDA came in at Rs 33 crore, expanding by 92.70% YoY and improving 13.37% sequentially. Total expenses posted a minor rise of 6.28% to Rs 199.08 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 179.73 crore, inching up 2.47% YoY, while employee benefits expense was at Rs 7.12 crore, tumbling by 19.64% YoY. For the TTM ended FY26, revenue from operations witnessed a strong growth of 40.21% to Rs 633.33 crore, while net profit saw a strong growth of 65.25% to Rs 32.62 crore, compared to previous TTM. EBITDA jumped by 5712% to Rs 94.54 crore, and PBT witnessed a strong rise of 70.97% to Rs 47.0 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 115.25 crore in FY26, as against Rs 29.06 crore in FY25. Fredun Pharmaceuticals Ltd rallied 265.10% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 2.64% during the same period.

Fredun Pharmaceuticals Ltd share price headed higher 5.45% to Rs 1109.75 after the company's net profit surged by 21.80% to Rs 13.13 crore, while revenue from operations improved marginally 8.25% to Rs 227.76 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 24.82 lakh crore, easing 6.18%. It has inched up 0.41% over last one week and moving up by 11.45% in last one month while the market capitalization of Fredun Pharmaceuticals Ltd has sharply increased by 22.33% and 40.82% in the same period respectively. Profit before tax (PBT) of Fredun Pharmaceuticals Ltd stood at Rs 20.55 crore in Q2 FY26, surging by 127.32% year-on-year, and expanding by 82.67% quarter-on-quarter. EBITDA came in at Rs 33 crore, rallying 92.70% YoY and rising by 13.37% sequentially. Total expenses grew marginally by 6.28% to Rs 199.08 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 179.73 crore, inching up 2.47% YoY, while employee benefits expense was at Rs 7.12 crore, tanking by 19.64% YoY. For the TTM ended FY26, revenue from operations soared by 40.21% to Rs 633.33 crore, while net profit jumped 65.25% to Rs 32.62 crore, compared to previous TTM. EBITDA jumped by 5712% to Rs 94.54 crore, and PBT witnessed a strong rise of 70.97% to Rs 47.0 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 115.25 crore in FY26, as against Rs 29.06 crore in FY25. Fredun Pharmaceuticals Ltd rallied 227.89% in last one year, significantly outperforming the benchmark BSE Sensex which has softened by 3.20% during the same period.

Fredun Pharmaceuticals Limited will hold a board meeting on Wednesday, August 5, 2026, to consider and approve the unaudited financial results (standalone and consolidated) for the quarter ended June 30, 2026, according to a regulatory filing with the BSE Limited. The trading window for the company's securities will remain closed for 48 hours after the financial results are declared, as per Securities and Exchange Board of India regulations.

Fredun Pharmaceuticals announced that the 39th Annual General Meeting(AGM) of the company will be held on 30 June 2026.